Table S1 from Distinct Mechanisms of Mismatch-Repair Deficiency Delineate Two Modes of Response to Anti–PD-1 Immunotherapy in Endometrial Carcinoma

Table S1 from Distinct Mechanisms of Mismatch-Repair Deficiency Delineate Two Modes of Response to Anti–PD-1 Immunotherapy in Endometrial Carcinoma

<p>Supplementary Table S1: Genomic and clinical characteristics of the study cohort.</p>

Saved in:

書目詳細資料
主要作者:	Ryan D. Chow (15109654) (author)
其他作者:	Tai Michaels (15122331) (author), Stefania Bellone (15122334) (author), Tobias M.P. Hartwich (15122337) (author), Elena Bonazzoli (15122340) (author), Akiko Iwasaki (15122343) (author), Eric Song (15122346) (author), Alessandro D. Santin (15122349) (author)
出版:	2025
主題:	Cancer Therapeutic Research and Development Immuno-oncology Gynecological Cancers Endometrial cancer Immunotherapy Translational Research
標簽:	添加標簽沒有標簽, 成為第一個標記此記錄!

相似書籍

Table S2 from Distinct Mechanisms of Mismatch-Repair Deficiency Delineate Two Modes of Response to Anti–PD-1 Immunotherapy in Endometrial Carcinoma
由: Ryan D. Chow (15109654)
出版: (2025)

Table S3 from Distinct Mechanisms of Mismatch-Repair Deficiency Delineate Two Modes of Response to Anti–PD-1 Immunotherapy in Endometrial Carcinoma
由: Ryan D. Chow (15109654)
出版: (2025)

Table S4 from Distinct Mechanisms of Mismatch-Repair Deficiency Delineate Two Modes of Response to Anti–PD-1 Immunotherapy in Endometrial Carcinoma
由: Ryan D. Chow (15109654)
出版: (2025)

Supplemental Table 1 from Allele-Specific Gene Regulation, Phenotypes, and Therapeutic Vulnerabilities in Estrogen Receptor Alpha–Mutant Endometrial Cancer
由: Zannel Blanchard (16617018)
出版: (2025)

Supplemental Table 2 from Allele-Specific Gene Regulation, Phenotypes, and Therapeutic Vulnerabilities in Estrogen Receptor Alpha–Mutant Endometrial Cancer
由: Zannel Blanchard (16617018)
出版: (2025)

Supplemental Table 3 from Allele-Specific Gene Regulation, Phenotypes, and Therapeutic Vulnerabilities in Estrogen Receptor Alpha–Mutant Endometrial Cancer
由: Zannel Blanchard (16617018)
出版: (2025)

Figure 1 from Preclinical Activity of Datopotamab Deruxtecan (Dato-DXd), an Antibody–Drug Conjugate Targeting TROP2, in Poorly Differentiated Endometrial Carcinomas
由: Niccolò G. Santin (22229756)
出版: (2025)

Figure 2 from Preclinical Activity of Datopotamab Deruxtecan (Dato-DXd), an Antibody–Drug Conjugate Targeting TROP2, in Poorly Differentiated Endometrial Carcinomas
由: Niccolò G. Santin (22229756)
出版: (2025)

Figure 3 from Preclinical Activity of Datopotamab Deruxtecan (Dato-DXd), an Antibody–Drug Conjugate Targeting TROP2, in Poorly Differentiated Endometrial Carcinomas
由: Niccolò G. Santin (22229756)
出版: (2025)

Figure 4 from Preclinical Activity of Datopotamab Deruxtecan (Dato-DXd), an Antibody–Drug Conjugate Targeting TROP2, in Poorly Differentiated Endometrial Carcinomas
由: Niccolò G. Santin (22229756)
出版: (2025)

Figure 5 from Preclinical Activity of Datopotamab Deruxtecan (Dato-DXd), an Antibody–Drug Conjugate Targeting TROP2, in Poorly Differentiated Endometrial Carcinomas
由: Niccolò G. Santin (22229756)
出版: (2025)

Table 1 from Preclinical Activity of Datopotamab Deruxtecan (Dato-DXd), an Antibody–Drug Conjugate Targeting TROP2, in Poorly Differentiated Endometrial Carcinomas
由: Niccolò G. Santin (22229756)
出版: (2025)

Supplemental Figure 1 from Preclinical Activity of Datopotamab Deruxtecan (Dato-DXd), an Antibody–Drug Conjugate Targeting TROP2, in Poorly Differentiated Endometrial Carcinomas
由: Niccolò G. Santin (22229756)
出版: (2025)

Supplemental Figure 2 from Preclinical Activity of Datopotamab Deruxtecan (Dato-DXd), an Antibody–Drug Conjugate Targeting TROP2, in Poorly Differentiated Endometrial Carcinomas
由: Niccolò G. Santin (22229756)
出版: (2025)

Table 2_Mutation profile and molecular heterogeneity in mismatch repair deficient endometrial carcinoma.xlsx
由: Yumeng Cai (5591276)
出版: (2025)

Table 1_Mutation profile and molecular heterogeneity in mismatch repair deficient endometrial carcinoma.xlsx
由: Yumeng Cai (5591276)
出版: (2025)

Image 1_Mutation profile and molecular heterogeneity in mismatch repair deficient endometrial carcinoma.tif
由: Yumeng Cai (5591276)
出版: (2025)

Table 3_Mutation profile and molecular heterogeneity in mismatch repair deficient endometrial carcinoma.docx
由: Yumeng Cai (5591276)
出版: (2025)

Image 3_Mutation profile and molecular heterogeneity in mismatch repair deficient endometrial carcinoma.tif
由: Yumeng Cai (5591276)
出版: (2025)

Image 2_Mutation profile and molecular heterogeneity in mismatch repair deficient endometrial carcinoma.tif
由: Yumeng Cai (5591276)
出版: (2025)

Image 5_Mutation profile and molecular heterogeneity in mismatch repair deficient endometrial carcinoma.jpg
由: Yumeng Cai (5591276)
出版: (2025)

Image 4_Mutation profile and molecular heterogeneity in mismatch repair deficient endometrial carcinoma.tif
由: Yumeng Cai (5591276)
出版: (2025)

Image 6_Mutation profile and molecular heterogeneity in mismatch repair deficient endometrial carcinoma.tif
由: Yumeng Cai (5591276)
出版: (2025)

Image 7_Mutation profile and molecular heterogeneity in mismatch repair deficient endometrial carcinoma.tiff
由: Yumeng Cai (5591276)
出版: (2025)

Table 1_Evaluation of microsatellite instability patterns in mismatch repair deficiency: a retrospective analysis of 285 endometrial cancers.docx
由: Cheng Wang (102692)
出版: (2025)

Supplementary Figure 1 from Antitumor Effect of Farletuzumab Ecteribulin in Molecular Subtypes of Endometrial Cancer Patient-Derived Xenograft Models
由: Shigehiro Yagishita (15088446)
出版: (2025)

Supplementary Figure 2 from Antitumor Effect of Farletuzumab Ecteribulin in Molecular Subtypes of Endometrial Cancer Patient-Derived Xenograft Models
由: Shigehiro Yagishita (15088446)
出版: (2025)

Supplementary Figure 3 from Antitumor Effect of Farletuzumab Ecteribulin in Molecular Subtypes of Endometrial Cancer Patient-Derived Xenograft Models
由: Shigehiro Yagishita (15088446)
出版: (2025)

Supplementary Figure 4 from Antitumor Effect of Farletuzumab Ecteribulin in Molecular Subtypes of Endometrial Cancer Patient-Derived Xenograft Models
由: Shigehiro Yagishita (15088446)
出版: (2025)

Supplementary Table S4 from Evolution and Co-occurrence of PI3K Pathway Gene Mutations in Endometrial Carcinoma Molecular Subtypes at the Single-Cell Level
由: Arnaud Da Cruz Paula (17316230)
出版: (2025)

Immune checkpoint inhibitors or targeted therapy by mismatch repair status in endometrial cancer: a meta-analysis
由: Yi Tang (55726)
出版: (2025)

Figure S1 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
由: Martina S.J. McDermott (15206951)
出版: (2025)

Figure S2 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
由: Martina S.J. McDermott (15206951)
出版: (2025)

Figure S3 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
由: Martina S.J. McDermott (15206951)
出版: (2025)

Figure S4 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
由: Martina S.J. McDermott (15206951)
出版: (2025)

Figure S5 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
由: Martina S.J. McDermott (15206951)
出版: (2025)

Figure S6 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
由: Martina S.J. McDermott (15206951)
出版: (2025)

Figure S7 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
由: Martina S.J. McDermott (15206951)
出版: (2025)

Figure S8 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
由: Martina S.J. McDermott (15206951)
出版: (2025)

Supplemental Tables 1 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
由: Martina S.J. McDermott (15206951)
出版: (2025)